POS1202 EXPERIENCE WITH COVID-19 IN GERMAN PAEDIATRIC RHEUMATOLOGY CENTRES
Authors: A. Klein, D. Windschall, W. Emminger, R. Berendes, J. Kuemmerle-Deschner, R. Trauzeddel, C. Rietschel, A. Kühn, M. Hufnagel, M. Sailer-Hoeck, T. Hospach, M. Haller, S. Mrusek, C. Sengler, K. Minden, G. Horneff
Journal: Annals of the Rheumatic Diseases (2021)

Background: COVID-19 is a major challenge worldwide. Although the risk for a severe disease course is low among children with COVID-19, symptoms may be exacerbated by underlying disease and/or immunosuppressive medication. We analysed clinical data from COVID-19 cases in among pediatric patients with juvenile idiopathic arthritis (JIA) in Germany reported to the BIKER registry. Objectives: This is an analysis of clinical data for 56 COVID-19 cases reported to the German BIKER registry from 29 German pediatric rheumatology centers and clinics from February 2020 to January 2021. Methods: The major task of the German BIKER (Biologics in Paediatric Rheumatology) Registry is surveillance of biologics used in pediatric rheumatology patients. Following the start of the COVID-19 pandemic in Germany, a survey was established to proactively interview all participating centers regarding the occurrence, presentation and outcome of SARS-CoV-2-infected children with rheumatic diseases. Initially, the interviews were conducted in weekly intervals, later bi-weekly. A standardized Adverse Event of Special Interest form was developed requesting biographic data, pre-treatment, current medication, data on clinical presentation, course, treatment and outcome of COVID-19 pediatric rheumatology patients. Results: In all, 56 patients with JIA and SARS-CoV-2 infection were reported (Table 1). Of these patients, 71% were 12 or more years old. Table 1. Patient characteristics. COVID-19 positive patients. JIA patients, n=56 n (%) Age 0-5 years / 6-11years / 12-18years 3 (5.4) / 13 (23.2) / 40 (71.4) JIA category •Systemic JIA 5 (8.9) •Oligoarthritis JIA 9 (16) •Polyarticular JIA 32 (57) •Enthesitis-related JIA 2 (3.6) •Psoriatic JIA 1 (1.8) •Unknown 7 (12.5) Uveitis (concomitant ) 4 (7.1) Treatment •DMARD / MTX 23/ 22 (41/39) •Biologics 29 (52) •TNF inhibitors 20 (36) •Tocilizumab 5 (8.9) •Abatacept 1 (1.8) •Anakinra 1 (1.8) •Ustekinumab 1 (1.8) •JAK inhibitors 1 (1.8) •Steroids 5 (8.9) Asymptomatic 13 (23.2) Hospitalized/ICU/Ventilation/Death 1/1/1/1 (1.8) At the time of infection, 41% of the patients received conventional DMARDs and 52% received biologics (Table 1). Forty-four patients (79%) received either a conventional DMARD or a biologic. Most patients had a polyarticular course of their JIA (57%). In 49 of the 56 cases (88%) COVID-19 was detected directly by PCR (n=46), by antigen test only (n=1) or an undisclosed method (n= 2). Six patients had detectable SARS-CoV2 antibodies and reported to have had typical symptoms. One patient tested negative but developed typical symptoms at approximately the same time a positive SARS-CoV-2 test was returned for a family member. Symptoms were reported in 43 of the 56 patients (77%): fever n=15, rhinitis n=14, cough n=12, headache n=10, loss of sense of taste and/or smell n=9, pharyngitis n=8, fatigue n=5, musculoskeletal pain n=5, GI symptoms n=2 (abdominal pain n=1, diarrhoea n=1), dizziness n=3, encephalitis/seizure/respiratory failure/death n=1. Thirteen patients (23%) were asymptomatic. A 3½ -year-old female patient initially diagnosed with systemic JIA developed intracranial oedema and respiratory failure. Her SARS-CoV2 PCR test was positive and pulmonary imaging displayed typical changes in lung texture. Before her SARS-CoV-2 infection, the patient was treated with methotrexate and low-dose steroids. Unfortunately, she died three days following hospital admission. Genetic testing revealed an inborn immunodeficiency. Except for this one patient, all other cases were treated as outpatients and no deaths were reported. Conclusion: Apart from one patient with an inborn immunodeficiency who died from her COVID-19 infection, no case of hospitalization or severe COVID-19 was reported in our cohort of JIA patients. At the time of COVID-19 diagnosis, nearly 80% of patients in our cohort had been treated with conventional DMARD and/or biologics. This seemed not to have a negative effect on severity or outcome of SARS-CoV2 infection. Acknowledgements: Thanks also for contributing Reports for this analysis to: Normi Brück, Frank Dressler, Ivan Foeldvari, Tilman Geikowski, Hermann Girschick, Johannes-Peter Haas, Tilmann Kallinich, Bernd-Ulrich Keck, Eggert Lilienthal, Anna-Hedrich Müller, Ulrich Neudorf, Nils Onken, Peggy Rühmer. Disclosure of Interests: None declared.